首页 | 本学科首页   官方微博 | 高级检索  
检索        

玻璃体腔内注射抗血管内皮生长因子治疗早产儿视网膜病复发的危险因素分析
引用本文:郝庆飞,陈静,阮鹏,李高攀,张静,陈浩明,郭宏湘,孙晓娟,程秀永.玻璃体腔内注射抗血管内皮生长因子治疗早产儿视网膜病复发的危险因素分析[J].中国当代儿科杂志,2022,24(11):1207-1212.
作者姓名:郝庆飞  陈静  阮鹏  李高攀  张静  陈浩明  郭宏湘  孙晓娟  程秀永
作者单位:郝庆飞, 陈静, 阮鹏, 李高攀, 张静, 陈浩明, 郭宏湘, 孙晓娟, 程秀永
摘    要:目的 探讨玻璃体腔内注射抗血管内皮生长因子(vascular endothelial growth factor,VEGF)治疗早产儿视网膜病(retinopathy of prematurity,ROP)的效果及复发的危险因素。 方法 回顾性收集2016年1月—2021年12月在郑州大学第一附属医院出生行抗VEGF治疗的ROP患儿159例的临床资料,根据首次抗VEGF治疗后随访周期内ROP复发与否分为复发组(24例)和非复发组(135例),比较分析2组临床资料,采用多因素logistic回归分析探讨抗VEGF治疗ROP复发的危险因素。 结果 经单次抗VEGF治疗后,所有159例患儿均显示附加病变消退。24例(15.1%)抗VEGF治疗后复发,复发平均时间为治疗后(8.4±2.6)周。多因素logistic回归分析显示,术前眼底出血、总用氧时间较长是ROP复发的危险因素(P<0.05),而妊娠高血压是保护因素(P<0.05)。 结论 玻璃体腔内注射抗VEGF治疗ROP是有效的。术前眼底出血和氧疗时间较长可增加ROP复发的风险,而对于妊娠高血压对ROP复发的影响,还需进一步研究证实。

关 键 词:早产儿视网膜病变  抗血管内皮生长因子  复发  早产儿  
收稿时间:2022-05-06

Risk factors for recurrence after intravitreal anti-vascular endothelial growth factor injection for retinopathy of prematurity
HAO Qing-Fei,CHEN Jing,RUAN Peng,LI Gao-Pan,ZHANG Jing,CHEN Hao-Ming,GUO Hong-Xiang,SUN Xiao-Juan,CHENG Xiu-Yong.Risk factors for recurrence after intravitreal anti-vascular endothelial growth factor injection for retinopathy of prematurity[J].Chinese Journal of Contemporary Pediatrics,2022,24(11):1207-1212.
Authors:HAO Qing-Fei  CHEN Jing  RUAN Peng  LI Gao-Pan  ZHANG Jing  CHEN Hao-Ming  GUO Hong-Xiang  SUN Xiao-Juan  CHENG Xiu-Yong
Institution:HAO Qing-Fei, CHEN Jing, RUAN Peng, LI Gao-Pan, ZHANG Jing, CHEN Hao-Ming, GUO Hong-Xiang, SUN Xiao-Juan, CHENG Xiu-Yong
Abstract:Objective To investigate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection in the treatment of retinopathy of prematurity (ROP) and the risk factors for recurrence. Methods A retrospective analysis was performed on the medical data of 159 infants with ROP who were born in the First Affiliated Hospital of Zhengzhou University and underwent anti-VEGF treatment from January 2016 to December 2021. According to the presence or absence of recurrence within the follow-up period after initial anti-VEGF treatment, they were divided into a recurrence group with 24 infants and a non-recurrence group with 135 infants. The medical data were compared between the two groups, and a multivariate logistic regression analysis was used to investigate the risk factors for the recurrence of ROP after anti-VEGF treatment. Results After one-time anti-VEGF treatment, all 159 infants showed regression of plus disease. Recurrence was observed in 24 infants (15.1%) after anti-VEGF treatment, with a mean interval of (8.4±2.6) weeks from treatment to recurrence. The multivariate logistic regression analysis showed that preoperative fundus hemorrhage and prolonged total oxygen supply time were risk factors for the recurrence of ROP (P<0.05), while gestational hypertension was a protective factor (P<0.05). Conclusions Intravitreal anti-VEGF injection is effective for ROP. Preoperative fundus hemorrhage and long duration of oxygen therapy may increase the risk of ROP recurrence, and further studies are needed to investigate the influence of gestational hypertension on the recurrence of ROP.
Keywords:Retinopathy of prematurity  Anti-vascular endothelial growth factor  Recurrence  Preterm infant  
点击此处可从《中国当代儿科杂志》浏览原始摘要信息
点击此处可从《中国当代儿科杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号